$2.45 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 95 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 76.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MYL | Buy | MYLAN N V | $151,397,000 | +6.5% | 7,654,065 | +2.5% | 6.17% | +20.9% |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $87,813,000 | -2.0% | 4,568,824 | +50.6% | 3.58% | +11.2% |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $55,903,000 | +307.2% | 2,589,291 | +315.0% | 2.28% | +362.3% |
| Buy | CLOVIS ONCOLOGY INCnote 2.500% 9/1 | $42,262,000 | +165.8% | 49,064,000 | +172.6% | 1.72% | +201.8% | |
| RARX | Buy | RA PHARMACEUTICALS INC | $40,868,000 | -20.7% | 1,728,019 | +0.9% | 1.67% | -9.9% |
| MIRM | New | MIRUM PHARMACEUTICALS INC | $34,696,000 | – | 3,448,912 | +100.0% | 1.42% | – |
| SILK | Buy | SILK ROAD MEDICAL INC | $31,862,000 | +31.8% | 979,480 | +96.3% | 1.30% | +49.5% |
| VCEL | Buy | VERICEL CORP | $31,506,000 | -19.4% | 2,081,000 | +0.6% | 1.28% | -8.5% |
| CNC | Buy | CENTENE CORP DEL | $31,165,000 | +96.1% | 720,400 | +137.8% | 1.27% | +122.6% |
| FATE | Buy | FATE THERAPEUTICS INC | $30,328,000 | -12.3% | 1,952,897 | +14.7% | 1.24% | -0.5% |
| ALEC | Buy | ALECTOR INC | $29,948,000 | -9.8% | 2,076,812 | +18.9% | 1.22% | +2.4% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $28,772,000 | -38.7% | 382,000 | +23.6% | 1.17% | -30.5% |
| TNDM | Buy | TANDEM DIABETES CARE INC | $26,797,000 | +172.4% | 454,334 | +197.9% | 1.09% | +209.6% |
| AXGN | Buy | AXOGEN INC | $22,992,000 | +30.3% | 1,842,330 | +106.7% | 0.94% | +47.8% |
| SWTX | New | SPRINGWORKS THERAPEUTICS INC | $22,783,000 | – | 1,050,888 | +100.0% | 0.93% | – |
| MOH | Buy | MOLINA HEALTHCARE INC | $21,621,000 | +0.7% | 197,056 | +31.4% | 0.88% | +14.3% |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $20,666,000 | +21.2% | 1,773,938 | +56.0% | 0.84% | +37.5% |
| WVE | Buy | WAVE LIFE SCIENCES LTD | $16,583,000 | -5.0% | 807,727 | +20.7% | 0.68% | +7.8% |
| TPTX | Buy | TURNING POINT THERAPEUTICS I | $14,572,000 | +24.5% | 387,545 | +34.8% | 0.59% | +41.4% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $13,008,000 | +5.2% | 268,100 | +14.1% | 0.53% | +19.4% |
| MNKKQ | Buy | MALLINCKRODT PUB LTD CO | $10,101,000 | -73.7% | 4,191,327 | +0.3% | 0.41% | -70.1% |
| INGN | New | INOGEN INC | $9,182,000 | – | 191,660 | +100.0% | 0.37% | – |
| GH | New | GUARDANT HEALTH INC | $8,043,000 | – | 126,000 | +100.0% | 0.33% | – |
| ATRC | New | ATRICURE INC | $7,302,000 | – | 292,777 | +100.0% | 0.30% | – |
| AIMT | New | AIMMUNE THERAPEUTICS INC | $7,109,000 | – | 339,480 | +100.0% | 0.29% | – |
| AVRO | New | AVROBIO INC | $7,060,000 | – | 500,000 | +100.0% | 0.29% | – |
| PRVB | New | PROVENTION BIO INC | $4,948,000 | – | 725,000 | +100.0% | 0.20% | – |
| ABMD | New | ABIOMED INC | $4,910,000 | – | 27,600 | +100.0% | 0.20% | – |
| FTSV | New | FORTY SEVEN INC | $4,815,000 | – | 750,000 | +100.0% | 0.20% | – |
| IGMS | New | IGM BIOSCIENCES INC | $4,438,000 | – | 250,000 | +100.0% | 0.18% | – |
| ALIM | Buy | ALIMERA SCIENCES INC | $4,000,000 | -25.7% | 7,062,607 | +16.7% | 0.16% | -16.0% |
| STIM | Buy | NEURONETICS INC | $2,821,000 | +41.8% | 339,512 | +113.5% | 0.12% | +62.0% |
| ATEC | New | ALPHATEC HOLDINGS INC | $2,693,000 | – | 536,517 | +100.0% | 0.11% | – |
| AGRX | New | AGILE THERAPEUTICS INC | $1,886,000 | – | 1,591,652 | +100.0% | 0.08% | – |
| CSTL | New | CASTLE BIOSCIENCES INC | $1,673,000 | – | 92,477 | +100.0% | 0.07% | – |
| VRAY | New | VIEWRAY INC | $1,098,000 | – | 378,623 | +100.0% | 0.04% | – |
| KMPH | New | KEMPHARM INC | $477,000 | – | 692,104 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.